Varilrix (live attenuated varicella zoster virus vaccine) / GSK - LARVOL DELTA

EBOLAPED: Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon (clinicaltrials.gov) - P1/2 | N=120 | Completed | Sponsor: Centre de Recherche Médicale de Lambaréné | Recruiting ➔ Completed | Trial completion date: Apr 2022 ➔ Aug 2022

Trial completion • Trial completion date • Infectious Disease • CCL2 • IL10 • IL1R1 • IL1RN • IL6

Assessment of attenuation of varicella-zoster virus vaccines based on genomic comparison. (PubMed, J Med Virol) - "To assess the attenuation of commercial VZV vaccines, genetic variants were comprehensively examined through high-throughput sequencing of viral DNA isolated from four VZV vaccines (Barycela, VarilRix, VariVax, and SKY Varicella). In particular, attenuation-associated 42 SNPs showed that Barycela, VarilRix, VariVax, and SKY Varicella are in ascending order regarding similarity with pOka-like genotypes, which in turn, might provide genomic evidence for the levels of attenuation. Finally, the phylogenetic network analysis demonstrated that genetic distances from the parental strain correlated with the attenuation levels of the vaccines."

Journal • Herpes Zoster • Infectious Disease • Varicella Zoster

The Long-Term Clinical and Economic Impact of Universal Varicella Vaccination in Slovenia. (PubMed, J Health Econ Outcomes Res) - "Six 2-dose UVV strategies, vs no vaccination, were considered over a 50-year period, including monovalent vaccination (Varivax [V-MSD] or Varilrix [V-GSK]) at ages 12 and 24 months, or monovalent vaccination at 15 months followed by monovalent or quadrivalent vaccination (ProQuad [MMRV-MSD] or Priorix- Tetra [MMRV-GSK]) at 5.5 years... All 2-dose UVV strategies were cost-effective compared with no vaccination from payer and societal perspectives, with V-MSD (15 months/5.5 years) being the most favorable from both perspectives. Policymakers should consider implementing UVV to reduce the burden of varicella disease in Slovenia."

HEOR • Journal • Herpes Zoster • Infectious Disease • Varicella Zoster

Relative efficacy of varicella vaccines: Network meta-analysis of randomized controlled trials. (PubMed, Curr Med Res Opin) - "Efficacy data were reported for four varicella-containing vaccines: Varivax (V-MSD, one- and two-dose), Varilrix (V-GSK, one-dose), Priorix-Tetra (MMRV-GSK, one-dose), and Sinovac (V-Sinovac, one-dose)...Among one-dose formulations, one-dose V-MSD was more effective than one-dose V-GSK. Policymakers should take into consideration differences in VE when implementing one- versus two-dose strategies in universal vaccination programs."

Journal • Retrospective data • Review • Varicella Zoster

Comparison of performance of varicella vaccines via infectious disease modeling. (PubMed, Vaccine) - "The model developed fits the long-term clinical trial data on breakthrough infections for both V-MSD and V-GSK, thus, allowing for the direct comparison of vaccine performance. We estimated that a single dose of V-MSD was more likely to provide permanent protection than a single dose of V-GSK, while the protection offered by two doses was similar for both vaccines."

Journal • Infectious Disease • Varicella Zoster